Valuation: Viyash Scientific Limited

Market Cap 88.8B 935M 835M 771M 700M 1.31B 1.33B 9.28B 3.67B 46.48B 3.51B 3.44B 147B P/E 2027 *
29.1x
P/E 2028 * 16.6x
Enterprise Value 88.8B 935M 835M 771M 700M 1.31B 1.33B 9.28B 3.67B 46.48B 3.51B 3.44B 147B EV / Sales 2027 *
2.28x
EV / Sales 2028 * 2.01x
Free-Float
44.4%
Yield 2027 *
-
Yield 2028 * -
1 day-2.07%
1 week-9.90%
Current month-13.74%
1 month-19.12%
3 months-20.81%
6 months-2.93%
Current year-2.26%
1 week 197
Extreme 197
229.85
1 month 197
Extreme 197
253.35
Current year 178.4
Extreme 178.4
297.9
1 year 178.4
Extreme 178.4
297.9
3 years 91.85
Extreme 91.85
297.9
5 years 61.8
Extreme 61.8
297.9
10 years 42.45
Extreme 42.45
336.4
Manager TitleAgeSince
Chief Executive Officer 62 16/12/2025
Director of Finance/CFO - 01/01/2026
Chief Tech/Sci/R&D Officer - 05/02/2026
Director TitleAgeSince
Chairman 78 25/08/2025
Director/Board Member 67 25/08/2020
Director/Board Member 57 11/04/2022
Change 5-day change 1-year change 3-year change Capi.($)
-2.07%-9.90%-1.14%+94.67% 957M
-2.54%+1.75%+56.75%+117.82% 1,165B
-1.42%+4.16%+36.73%+72.42% 645B
+0.16%+0.79%+24.91%+95.34% 504B
-0.31%+2.95%+39.36%+63.56% 380B
-1.34%+0.06%+65.81%+41.49% 363B
-0.68%+1.67%+22.07%+50.94% 297B
-1.20%+0.99%+2.26%+22.95% 269B
-1.79%+1.20%+48.41%+57.55% 237B
-0.73%-0.85%+28.47%+100.57% 195B
Average -1.01%+1.49%+32.36%+71.73% 405.64B
Weighted average by Cap. -0.74%+3.17%+40.77%+80.34%

Financials

2027 *2028 *
Net sales 38.99B 411M 367M 339M 307M 575M 584M 4.08B 1.61B 20.41B 1.54B 1.51B 64.44B 44.28B 466M 416M 384M 349M 653M 663M 4.63B 1.83B 23.18B 1.75B 1.71B 73.18B
Net income 3.44B 36.22M 32.32M 29.85M 27.09M 50.73M 51.5M 359M 142M 1.8B 136M 133M 5.68B 5.65B 59.47M 53.07M 49.01M 44.47M 83.29M 84.56M 590M 233M 2.95B 223M 218M 9.33B
Net Debt - -
Projected Income Statement - Annual - Viyash Scientific Limited
Logo Viyash Scientific Limited
Viyash Scientific Limited, formerly SeQuent Scientific Limited, is an India-based integrated pharmaceutical company with a global footprint, operating in the domains of animal health (active pharmaceutical ingredients (APIs), and finished dosage formulations) and analytical services. The Company has eight manufacturing facilities, based in India, Turkey, Brazil, Spain and Germany. It is focused on various therapies, such as targeted are anthelmintics (endo and ecto parasiticides), anti-protozoals, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives and dermatology. It specializes in analytical and bioanalytical services to support the API, pharmaceutical, personal care and nutraceutical companies. It offers analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopoeia monographs, customer-developed methods or in-house method development.
Employees
2,900
Date Price Change Volume
23/10/26 INR 203.45 -2.07% 502,871
22/10/26 INR 207.75 -3.03% 162,356
21/10/26 INR 214.25 -3.08% 222,677
19/10/26 INR 221.05 -2.21% 177,242
16/10/26 INR 226.05 +0.11% 102,560
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Viyash Scientific Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
203.45INR
Average target price
326.00INR
Spread / Average Target
+60.24%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Viyash Scientific Limited
  1. Stock Market
  2. Stocks
  3. VIYASH Stock